Clinical trial NCT05565599: An Early Feasibility Study Evaluating the Safety and Efficacy of the Laminar Left Atrial Appendage Closure System in Subjects With Non-Valvular Atrial Fibrillation
Official title: An Early Feasibility Study Evaluating the Safety and Efficacy of the Laminar Left Atrial Appendage Closure System in Subjects With Non-Valvular Atrial Fibrillation
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Non-valvular Atrial Fibrillation
Lead sponsor: Laminar, Inc.
Sponsor class: INDUSTRY
First posted: 2022-10-04
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is an early feasibility study is to evaluate the safety and effectiveness of the Laminar Left Atrial Appendage Closure System to treat patients with non-valvular atrial fibrillation that cannot take, or a have a reason to seek an alternative, to anticoagulant medications.

Detailed description: Left atrial appendage closure (LAAC) is an approved therapy for stroke prevention in atrial fibrillation patients who are recommended for chronic oral anticoagulation therapy (OAC), but are non-eligible or have an appropriate rationale to seek a non-pharmacologic alternative to chronic oral anticoagulants in accordance with evidence-based decision-making criteria and current scientific guidelines.

The objective of this study is to evaluate the safety and effectiveness of the Laminar Left Atrial Appendage Closure System to treat patients with non-valvular atrial fibrillation who are deemed appropriate for LAAC to reduce the risk of stroke and systemic embolism.

Patients will be followed for 5 years after the procedure.

Eligibility criteria: Inclusion Criteria:

1. Documented non-valvular AF, defined as AF (paroxysmal, persistent, or permanent) in the absence of moderate-to-severe mitral stenosis or a mechanical heart valve.
2. Subject ≥18 years old.
3. CHA2DS2-VASc score ≥ 2 in men and ≥ 3 in women.
4. Subject is recommended for chronic oral anticoagulation therapy (OAC) but is not eligible or has an appropriate rationale to seek a non-pharmacologic alternative to chronic OAC.
5. Subject deemed appropriate for LAA closure by the Site Heart Team using an evidenced based decision-making tool.
6. Subject eligible for the protocol-specified post-procedural antithrombotic regimen.
7. Subject or Legally Authorized Representative informed of the nature of the study, is willing and able to comply with the protocol, and has provided written informed consent per Institutional Review Board (IRB) requirements.

Exclusion Criteria:

1. Single episode, transient, or reversible AF (e.g., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures).
2. Stroke or transient ischemic attack within 90 days before the index procedure.
3. Myocardial infarction or unstable angina within 90 days before the index procedure.
4. Renal insufficiency, defined as estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m2, or dialysis at the time of screening.
5. Active infection with bacteremia.
6. Confirmed COVID-19 infection within 10 days before the index procedure. Coexisting Cardiovascular Disease
7. Cardiac tumor
8. History of mitral valve or other severe cardiac valvular disease requiring intervention or presence of prosthetic mechanical valve.
9. Medical condition (other than AF) that mandates chronic oral anticoagulation (e.g., history of unprovoked deep vein thrombosis or pulmonary embolism, or mechanical heart valve).
10. Severe heart failure (New York Heart Association Class IV).
11. Symptomatic carotid artery disease (\>50% diameter reduction with prior ipsilateral stroke or TIA) or asymptomatic carotid artery disease (diameter reduction of \>70%).

    Previous or Planned Interventions
12. Previous AF ablation procedure in the 90 days before the index procedure date or need for AF ablation to be performed in less than 90 days after the index procedure.
13. Recent (within 30 days before the index procedure) or planned (within 60 days after the index procedure) cardiac or non-cardiac interventional or surgical procedure.
14. Intracardiac thrombus or dense spontaneous echo contrast visualized by TEE within 2 days before the index procedure.
15. Left ventricular ejection fraction (LVEF) \<30%.
16. Circumferential pericardial effusion \>10 mm or symptomatic pericardial effusion, signs or symptoms of acute or chronic pericarditis, or evidence of tamponade physiology.
17. Complex atheroma with mobile plaque of the aorta.
18. Interatrial communication, atrial septal defect, or patent foramen ovale that warrants closure.
19. Vascular access precluding delivery of implant with catheter-based system
20. Presence of inferior vena cava (IVC) filter that would interfere with Laminar sheath insertion.
21. Subject unable to undergo general anesthesia.
22. Subject with condition which precludes adequate transesophageal echocardiographic (TEE) assessment.
23. Known allergy, hypersensitivity or contraindication to aspirin, heparin, or device materials (e.g., nickel, titanium).
24. Contrast sensitivity that cannot be adequately pre-medicated.
25. Bleeding diathesis or coagulopathy
26. Thrombocytopenia (platelet count \<75,000 cells/mm3), thrombocytosis (\>700,000 cells/mm3), or leukopenia (white blood cell count \<3,000 cells/mm3).
27. Pregnant or nursing and those who plan pregnancy in the period up to 1 year following the index procedure. Subjects of childbearing potential must have a negative pregnancy test (per site standard test) within 7 days before index procedure.
28. Known other medical illness or known history of substance abuse that may cause non-compliance with the protocol or protocol-specified medication regimen, confound the data interpretation, or is associated with a life expectancy of less than 1 year.
29. Current participation in another investigational drug or device study that in the opinion of the investigator could confound the data interpretation.

Primary outcomes:
measure: Composite Adverse Events
timeFrame: 45 days
measure: Composite Adverse Events
timeFrame: 12 months
measure: LAA Closure Rate
timeFrame: 45 days
measure: LAA Closure Rate
timeFrame: 12 months
measure: LAA Closure Rate
timeFrame: 45 days
measure: Composite of Ischemic Stroke or System Embolism
timeFrame: 12 months
Secondary outcomes:
measure: Device-Related Thrombus
timeFrame: 45 days
measure: Device-Related Thrombus
timeFrame: 12 months
Other outcomes:
Locations:
city: Tucson
country: United States
facility: Tucson Medical Center
state: Arizona
city: Jonesboro
country: United States
facility: St. Bernards Medical Center
state: Arkansas
city: La Jolla
country: United States
facility: Scripps Health
state: California
city: Sacramento
country: United States
facility: UC Davis Medical Center
state: California
city: Thousand Oaks
country: United States
facility: Los Robles Hospital & Medical Center
state: California
city: New York
country: United States
facility: The Mount Sinai Hospital
state: New York
city: New York
country: United States
facility: Columbia U. Medical Center / NY Presbyterian Hospital
state: New York
Study officials:
References: